Search Results

Tempo Therapeutics, Inc. (“Tempo”), a leading innovator in tissue engineering and regenerative medicine, today announced the addition of Eric I. Richman, MBA to its board of directors.

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to evaluate the safety and efficacy of pitolisant as a treatment for excessive daytime sleepiness (EDS) and behavioral symptoms in patients aged six years and older with Prader-Willi syndrome (PWS).

Tempo Therapeutics, Inc (“Tempo”) a leading innovator in tissue engineering and regenerative medicine, today announced the successful completion of its $12 million Series A equity financing round, led by Galaxy-Sirius Partners and Johnson & Johnson Innovation – JJDC, Inc. (JJDC).

Tempo Bioscience, Inc., a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell derived cell products and affiliated cell-based services.

Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services.

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, will help AbbVie as it builds a regulatory case for the D1/D5 dopamine receptor agonist.

Staff cuts will leave IGM Biosciences with 37 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.